There’s a fundamental difference in opinion in modern MS treatment. On one hand, we have a treatment strategy defined by what amounts to a “wait and see” approach. In this…
Read More
This past month, the MSYPN met with RMMSC Board Chair, Del Arnold, and Board Member, Erica Tarpey. Del and Erica discussed their careers, what led them to the RMMSC board, and…
Medical appointments tend to be too short to address all our concerns and care does not always feel patient-centered. In an effort to reme-dy these common experiences and give patients…
One of the most difficult decisions for someone who’s been living with MS for a long time is whether or not to discontinue their treatment with disease modifying therapies (DMTs)….
As we develop treatment strategies that rely on early diagnosis, it’s more important than ever that we identify MS as quickly as possible — and that means watching for common…
This issue of InforMS describes the serious efforts of expert physicians to identify the best strategies to treat people with multiple sclerosis. Unfortunately, however, there is another critical decision maker…
An Interview with Dr. Roger Enoka with the Neurophysiology of Movement Laboratory at University of Colorado Boulder campus Dr. Roger Enoka, a professor at the University of Colorado Boulder, has…
Quite a bit’s going on in the world of disease modifying therapies (DMTs), and we’ve prepared a brief update for you. Read on for more about Gilenya’s FDA approval for…
The Rocky Mountain MS Center hosted the 2018 Spring Education Summit in Aurora on Saturday, May 12. We’ve archived the main content of the Summit to share with everyone that…
Join RMMSC Medical Director Dr. Timothy Vollmer for an in-depth look at disease modifying therapies (DMTs) – the front line in our fight against MS. This webinar will give you…
You're Reading:
About the Author
This content was compiled by Rocky Mountain MS Center staff members.